Akorn, Lundbeck deal

Akron's Oak Pharmaceuticals Inc. subsidiary acquired three off-patent injectables from H. Lundbeck's U.S. subsidiary - Nembutal pentobarbital, Diuril chlorothiazide and Cogentin benzotropine mesylate...